Summit Therapeutics (NASDAQ: SMMT)
Summit Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Summit Therapeutics Company Info
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
News & Analysis
1 Monster Stock in the Making to Buy and Hold
This biotech company was relatively unknown a few years ago.
Investing in Biotech Stocks in 2025
Is Summit Therapeutics a Buy, Sell, or Hold Now?
Western results for ivonescimab aren't lining up with the huge survival benefit measured in China.
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
2 Soaring Stocks With More Upside Potential to Buy and Hold
Why Summit Therapeutics Stock Soared 8% Higher Today
Why Summit Therapeutics Stock Tanked Today
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.